DiscoverCME in Minutes: Education in Primary CareTerry Faleye, MPAS, PA-C / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Beyond Biologics for Psoriasis and PsA: TYK2 Inhibitors and Practical Considerations for Personalizing Care
Terry Faleye, MPAS, PA-C / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Beyond Biologics for Psoriasis and PsA: TYK2 Inhibitors and Practical Considerations for Personalizing Care

Terry Faleye, MPAS, PA-C / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Beyond Biologics for Psoriasis and PsA: TYK2 Inhibitors and Practical Considerations for Personalizing Care

Update: 2025-11-19
Share

Description

Please visit answersincme.com/860/100752367-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of psoriatic disease discuss challenges in treatment, emerging TYK2 inhibitor therapies, and evidence-based strategies to optimize patient care. Upon completion of this activity, participants should be better able to: Recognize how nurse practitioners and physician associates can help address barriers to care and enhance outcomes for patients with moderate to severe plaque psoriasis; Differentiate TYK2 signaling from JAK pathways and explain the relevance of these distinctions in clinical outcomes; Evaluate the impact of emerging data on TYK2 inhibitors in shaping therapeutic strategies for psoriatic disease; and Apply strategies for aligning TYK2 inhibitor therapy with patient needs and multidisciplinary care plans.
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Terry Faleye, MPAS, PA-C / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Beyond Biologics for Psoriasis and PsA: TYK2 Inhibitors and Practical Considerations for Personalizing Care

Terry Faleye, MPAS, PA-C / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Beyond Biologics for Psoriasis and PsA: TYK2 Inhibitors and Practical Considerations for Personalizing Care

Answers in CME